13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001274403
Total reported value
$1.1B
$1.1B
10 檔
52.6%
The Q1 2026 SEC filing reveals that ARCH Venture Management, LLC held a total portfolio value of $1.1B, covering 10 public equity positions.
During Q1 2026, ARCH Venture Management, LLC performed routine portfolio adjustments (1 new buys, 1 additions, 2 trims, and 0 full exits), keeping overall allocation balanced.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MAZE | Maze Therapeutics Inc | Stock-Other | 18.16% | -6.98% | — | |
| 2 | RAPP | Rapport Therapeutics Inc | Stock-Other | 17.23% | -3.11% | — | |
| 3 | VIR | Vir Biotechnology Inc | Stock-Other | 17.09% | -5.33% | — | |
| 4 | ERAS | Erasca Inc | Stock-Other | 16.95% | -5.14% | -35.86% | |
| 5 | BEAM | Beam Therapeutics Inc | Stock-Other | 15.98% | -1.82% | — | |
| 6 | LYEL | Lyell Immunopharma Inc | Stock-Other | 9.62% | -5.48% | +17.69% | |
| 7 | GENB | Generate Biomedicines Inc | Stock-Other | 3.59% | -0.61% | — | |
| 8 | TXG | 10x Genomics Inc-class A | Stock-Other | 0.68% | +0.08% | -70.46% | |
| 9 | GOSS | Gossamer Bio Inc | Stock-Other | 0.39% | -0.27% | — | |
| 10 | QTTB | Q32 Bio Inc | Stock-Other | 0.30% | -0.30% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ERAS | Erasca Inc | +10.6% | -35.86% | Trim |
| 2 | VIR | Vir Biotechnology Inc | +5.1% | — | Unchanged |
| 3 | QTTB | Q32 Bio Inc | +0.1% | — | Unchanged |
| 4 | RAPP | Rapport Therapeutics Inc | -0.1% | — | Unchanged |
| 5 | TXG | 10x Genomics Inc-class A | -1.2% | -70.46% | Trim |
| 6 | BEAM | Beam Therapeutics Inc | -3.3% | — | Unchanged |
| 7 | LYEL | Lyell Immunopharma Inc | -3.4% | +17.69% | Add |
| 8 | GOSS | Gossamer Bio Inc | -3.4% | — | Unchanged |
| 9 | MAZE | Maze Therapeutics Inc | -8% | — | Unchanged |
| 10 | GENB | Generate Biomedicines Inc | — | NEW | New buy |
According to official SEC Form 13F filings, ARCH Venture Management, LLC reported a total U.S. public equity portfolio value of $1.1B across 10 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MAZE, RAPP, VIR) accounted for 52.6% of total reported equity market value during Q1 2026.
Top New Position Initiated
GENB
市值: $24.3M
Top Position Liquidated / Trimmed
ERAS
前期市值: $41.1M
During Q1 2026, ARCH Venture Management, LLC's top holdings by market value included MAZE (18.2%)、RAPP (17.2%)、VIR (17.1%). The largest single position, MAZE, represented 18.2% of total portfolio value.
In Q1 2026, ARCH Venture Management, LLC made 4 total portfolio adjustments, initiating 1 new buys, adding to 1 positions, trimming 2 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.